TIDMSN.
Smith & Nephew Plc
04 October 2017
Wound Expert Panel* reports biofilms, which delay wound healing,
are far more prevalent than previously understood, and publishes
new consensus on detection and treatment best practice
4 October 2017
Smith & Nephew (LSE:SN, NYSE:SNN), the global medical
technology business, welcomes the recent publication of the Wound
Biofilm Expert Panel's Consensus guidelines for the identification
and treatment of biofilms in chronic non-healing wounds.(1) This
paper is one of the first comprehensive insights into the detection
and treatment of wound biofilm.
Biofilms are clusters of bacteria embedded in a protective
matrix, (2) their presence in chronic wounds are linked to delayed
healing.(3,4) Moreover, biofilms provide a complex treatment
challenge to wound care clinicians as they are tolerant to
antimicrobial treatments(5-7) and the host immune
response.(8,9)
At least 78% of chronic wounds have been found to contain
biofilm,(10) a figure far in excess of previously understood
levels.
The Expert Panel was formed in late 2015 to improve scientific
understanding of biofilms and to recommend improved clinical
practice. Comprising of ten global leading experts from both
scientific and clinical backgrounds, the Expert Panel's Consensus
guidelines for the identification and treatment of biofilms in
chronic non-healing wounds have now been published in the eminent
journal Wound Repair and Regeneration journal.
Professor Gregory Schultz, Director of the Institute for Wound
Research at the University of Florida and Chair of the panel
commented: "Although four in five chronic wounds contain biofilm,
they are often not identified, resulting in ineffective treatment.
This document will have a tremendous impact helping both
researchers and clinicians better understand biofilms, how to treat
them and how to convert chronic wounds to healing wounds."
"Biofilm is a hot topic in wound care, there was a need for a
consensus to bring clarity and guidance to healthcare professionals
working to restore the quality of life of millions of patients
around the world with non-healing chronic wounds," said Andy
Weymann, Chief Medical Officer of Smith & Nephew. "Smith &
Nephew is proud to support healthcare professionals through the
development of both educational resources and advanced wound
management products."
Recent data have shown IODOSORB(TM) and IODOFLEX(TM) dressings
from Smith & Nephew, to be effective against biofilm in the
laboratory,(5, 11-13) and in the clinical setting to have an impact
on biofilm in diabetic foot ulcers.(14) Cadexomer Iodine has long
been demonstrated, at the highest level of evidence, to be an
effective treatment in chronic wounds. (15)
*funded by an educational grant from Smith & Nephew
- ends -
Enquiries
Media
Dave Snyder
Smith & Nephew +1 (978) 749-1440
About Smith & Nephew
Smith & Nephew is a global medical technology business
dedicated to helping healthcare professionals improve people's
lives. With leadership positions in Orthopaedic Reconstruction,
Advanced Wound Management, Sports Medicine and Trauma &
Extremities, Smith & Nephew has around 15,000 employees and a
presence in more than 100 countries. Annual sales in 2016 were
almost $4.7 billion. Smith & Nephew is a member of the FTSE100
(LSE:SN, NYSE:SNN).
For more information about Smith & Nephew, please visit our
website www.smith-nephew.com, follow @SmithNephewplc on Twitter or
visit SmithNephewplc on Facebook.com.
To learn more about what we do to help reduce biofilm, please
visit www.closertozero.com
Forward-looking Statements
This document may contain forward-looking statements that may or
may not prove accurate. For example, statements regarding expected
revenue growth and trading margins, market trends and our product
pipeline are forward-looking statements. Phrases such as "aim",
"plan", "intend", "anticipate", "well-placed", "believe",
"estimate", "expect", "target", "consider" and similar expressions
are generally intended to identify forward-looking statements.
Forward-looking statements involve known and unknown risks,
uncertainties and other important factors that could cause actual
results to differ materially from what is expressed or implied by
the statements. For Smith & Nephew, these factors include:
economic and financial conditions in the markets we serve,
especially those affecting health care providers, payers and
customers; price levels for established and innovative medical
devices; developments in medical technology; regulatory approvals,
reimbursement decisions or other government actions; product
defects or recalls or other problems with quality management
systems or failure to comply with related regulations; litigation
relating to patent or other claims; legal compliance risks and
related investigative, remedial or enforcement actions; disruption
to our supply chain or operations or those of our suppliers;
competition for qualified personnel; strategic actions, including
acquisitions and dispositions, our success in performing due
diligence, valuing and integrating acquired businesses; disruption
that may result from transactions or other changes we make in our
business plans or organisation to adapt to market developments; and
numerous other matters that affect us or our markets, including
those of a political, economic, business, competitive or
reputational nature. Please refer to the documents that Smith &
Nephew has filed with the U.S. Securities and Exchange Commission
under the U.S. Securities Exchange Act of 1934, as amended,
including Smith & Nephew's most recent annual report on Form
20-F, for a discussion of certain of these factors. Any
forward-looking statement is based on information available to
Smith & Nephew as of the date of the statement. All written or
oral forward-looking statements attributable to Smith & Nephew
are qualified by this caution. Smith & Nephew does not
undertake any obligation to update or revise any forward-looking
statement to reflect any change in circumstances or in Smith &
Nephew's expectations.
Trademark of Smith & Nephew. Certain marks registered US
Patent and Trademark Office.
References
1. Schultz et al. Wound Repair Regen (2017); accepted article
2. Burmølle, M. et al. FEMS Immunol. Med. Microbiol. 59,(2010);
3. Roche ED, et al. Wound Repair Regen 2012; 20: 537-43.
4. Schierle CF, et al. Wound Repair Regen. 2009;17: 354-9.
5 Phillips PL et al. Int Wounds J (2013):1-15;
6. Stewart, P. S. & Costerton, J. W.) 358, 135-8 (2001).
7. Wolcott, R. D. et al. J. Wound Care 19, 320-8 (2010).
8. Jesaitis, A. J. et al. J. Immunol. 171, 4329-39 (2003).
9. Bjarnsholt, T. et al. Microbiology 151, 373-383 (2005).
10. Malone, M. et al. J. Wound Care 26, 20-25 (2017).
11. Fitzgerald, D. J. et al. Wound Repair Regen. 1-40 (2016). doi:10.1111/wrr.12497
12. Schultz, G. & Yang. Poster presented at WUWHS Florence (2016)
13. Oates J.L. et al. Poster presented at SAWC, Atlanta.(2016);
14. Lantis, J. C. et al. Poster presented at WUWHS Florence (2016).
15. O'Meara, S. et al.. Cochrane database Syst. Rev. 1, CD003557 (2014).
This information is provided by RNS
The company news service from the London Stock Exchange
END
NRAFSEFDDFWSEIS
(END) Dow Jones Newswires
October 04, 2017 03:00 ET (07:00 GMT)
Smith and Nephew (NYSE:SNN)
Historical Stock Chart
From Aug 2024 to Sep 2024
Smith and Nephew (NYSE:SNN)
Historical Stock Chart
From Sep 2023 to Sep 2024